Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis
12.01.2015
No difference was found between the two cohorts regarding duration of benefit from treatment (primary 9.47 weeks vs. secondary 9.63 weeks, p50.88).
Perceived peak-dose benefit was more commonly reported as ‘‘very much improved’’ in secondary patients, but this was not significant (p50.13). Higher BoNT dosages were required in both groups over time, with a mean increase of 20.5% in primary and 26.5% in secondary blepharospasm. Ptosis (8%) and diplopia (6%) were the most common reported side effects. Mean follow-up in years was similar between groups, 3.6 years for primary vs. 2.4 years for secondary blepharospasm (p50.17).
Автор: Daniel Martinez-Ramirez, Juan C. Giugni, Erin Hastings, Aparna Wagle Shukla, Irene A. Malaty, Michael S. Okun, & Ramon L. Rodriguez
Год публикации: 2014
Файл: Загрузить